Tailored HIV-1 Vectors for Genetic Modification of Primary Human Dendritic Cells and Monocytes

ABSTRACT Monocyte-derived dendritic cells (MDDCs) play a key role in the regulation of the immune system and are the target of numerous gene therapy applications. The genetic modification of MDDCs is possible with human immunodeficiency virus type 1 (HIV-1)-derived lentiviral vectors (LVs) but requires high viral doses to bypass their natural resistance to viral infection, and this in turn affects their physiological properties. To date, a single viral protein is able to counter this restrictive phenotype, Vpx, a protein derived from members of the HIV-2/simian immunodeficiency virus SM lineage that counters at least two restriction factors present in myeloid cells. By tagging Vpx with a short heterologous membrane-targeting domain, we have obtained HIV-1 LVs incorporating high levels of this protein (HIV-1-Src-Vpx). These vectors efficiently transduce differentiated MDDCs and monocytes either as previously purified populations or as populations within unsorted peripheral blood mononuclear cells (PBMCs). In addition, these vectors can be efficiently pseudotyped with receptor-specific envelopes, further restricting their cellular tropism almost uniquely to MDDCs. Compared to conventional HIV-1 LVs, these novel vectors allow for an efficient genetic modification of MDDCs and, more importantly, do not cause their maturation or affect their survival, which are unwanted side effects of the transduction process. This study describes HIV-1-Src-Vpx LVs as a novel potent tool for the genetic modification of differentiated MDDCs and of circulating monocyte precursors with strong potential for a wide range of gene therapy applications.

[1]  W. Greene,et al.  Abortive HIV Infection Mediates CD4 T Cell Depletion and Inflammation in Human Lymphoid Tissue , 2010, Cell.

[2]  R. König,et al.  SAMHD1 restricts HIV-1 infection in resting CD4+ T cells , 2012, Nature Medicine.

[3]  Baek Kim,et al.  The Vpx Lentiviral Accessory Protein Targets SAMHD1 for Degradation in the Nucleus , 2012, Journal of Virology.

[4]  F. Diaz-Griffero,et al.  Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac , 2012, Retrovirology.

[5]  Michael Emerman,et al.  The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. , 2012, Cell host & microbe.

[6]  Frédéric Delsuc,et al.  Evolutionary and Functional Analyses of the Interaction between the Myeloid Restriction Factor SAMHD1 and the Lentiviral Vpx Protein , 2012 .

[7]  F. Cosset,et al.  Measles Virus Glycoprotein-Pseudotyped Lentiviral Vectors Are Highly Superior to Vesicular Stomatitis Virus G Pseudotypes for Genetic Modification of Monocyte-Derived Dendritic Cells , 2012, Journal of Virology.

[8]  Baek Kim,et al.  SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates , 2012, Nature Immunology.

[9]  R. König,et al.  SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-Goutières Syndrome Are Highly Susceptible to HIV-1 Infection , 2011, PLoS pathogens.

[10]  Geoff Kelly,et al.  HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase , 2011, Nature.

[11]  J. Darlix,et al.  APOBEC3A Is a Specific Inhibitor of the Early Phases of HIV-1 Infection in Myeloid Cells , 2011, PLoS pathogens.

[12]  B. Sobhian,et al.  SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx , 2011, Nature.

[13]  M. Washburn,et al.  Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein , 2011, Nature.

[14]  Andrea Cimarelli,et al.  A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1–derived lentiviral vectors , 2011, Nature Protocols.

[15]  J. Boudreau,et al.  Engineering dendritic cells to enhance cancer immunotherapy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[16]  N. Bhardwaj,et al.  Human Immunodeficiency Virus Type 1 Modified To Package Simian Immunodeficiency Virus Vpx Efficiently Infects Macrophages and Dendritic Cells , 2011, Journal of Virology.

[17]  D. Levy,et al.  A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells , 2010, Nature.

[18]  K. Cichutek,et al.  Functional HIV‐2‐ and SIVsmmPBj‐ derived lentiviral vectors generated by a novel polymerase chain reaction‐based approach , 2010, The journal of gene medicine.

[19]  E. Flory,et al.  Interaction of Vpx and Apolipoprotein B mRNA-editing Catalytic Polypeptide 3 Family Member A (APOBEC3A) Correlates with Efficient Lentivirus Infection of Monocytes , 2010, The Journal of Biological Chemistry.

[20]  K. Byth,et al.  HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. , 2009, Blood.

[21]  A. Bergamaschi,et al.  The Human Immunodeficiency Virus Type 2 Vpx Protein Usurps the CUL4A-DDB1DCAF1 Ubiquitin Ligase To Overcome a Postentry Block in Macrophage Infection , 2009, Journal of Virology.

[22]  F. Cosset,et al.  Strategies for targeting lentiviral vectors. , 2008, Current gene therapy.

[23]  K. Cichutek,et al.  Targeted cell entry of lentiviral vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Rajnish Kaushik,et al.  Primate Lentiviral Vpx Commandeers DDB1 to Counteract a Macrophage Restriction , 2008, PLoS pathogens.

[25]  Smita Srivastava,et al.  Lentiviral Vpx Accessory Factor Targets VprBP/DCAF1 Substrate Adaptor for Cullin 4 E3 Ubiquitin Ligase to Enable Macrophage Infection , 2008, PLoS pathogens.

[26]  D. Baltimore,et al.  Engineered lentivector targeting of dendritic cells for in vivo immunization , 2008, Nature Biotechnology.

[27]  K. Cichutek,et al.  Impact of viral accessory proteins of SIVsmmPBj on early steps of infection of quiescent cells. , 2007, Virology.

[28]  M. Dullaers,et al.  Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. , 2007, Human gene therapy.

[29]  Zhengfan Jiang,et al.  Vesicular stomatitis virus glycoprotein G activates a specific antiviral Toll-like receptor 4-dependent pathway. , 2007, Virology.

[30]  J. Darlix,et al.  Retrovirology BioMed Central , 2006 .

[31]  A. Cunningham,et al.  HIV Induces Maturation of Monocyte-Derived Dendritic Cells and Langerhans Cells1 , 2006, The Journal of Immunology.

[32]  J. Darlix,et al.  With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIVMAC , 2006, Gene Therapy.

[33]  U. Tschulena,et al.  Stable transduction of primary human monocytes by simian lentiviral vector PBj. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  D. Larkin,et al.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. , 2005, Blood.

[35]  Lung-Ji Chang,et al.  Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells , 2004, Retrovirology.

[36]  P. Mangeot,et al.  High levels of transduction of human dendritic cells with optimized SIV vectors. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  K. Kuhen,et al.  Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. , 2000, Blood.

[38]  S. Chen,et al.  Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  J. Wakefield,et al.  Vpx is required for dissemination and pathogenesis of SIVSM PBj: Evidence of macrophage-dependent viral amplification , 1998, Nature Medicine.

[40]  F. Gage,et al.  Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Mills,et al.  Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes , 1996, Journal of virology.

[42]  J. Wills,et al.  The membrane-binding domain of the Rous sarcoma virus Gag protein , 1996, Journal of virology.

[43]  S. Mizutani,et al.  Unfarnesylated transforming Ras mutant inhibits the Ras‐signaling pathway by forming a stable Ras·Raf complex in the cytosol , 1996, FEBS letters.

[44]  G. Rindi,et al.  Influence of MA internal sequences, but not of the myristylated N-terminus sequence, on the budding site of HIV-1 Gag protein. , 1994, Biochemical and biophysical research communications.

[45]  M. Resh,et al.  Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids , 1994, Journal of virology.

[46]  W. O'brien,et al.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors , 1994, Journal of virology.

[47]  Stephen W. Martin,et al.  Cytotoxic T Lymphocytes , 1988 .

[48]  P. Mangeot,et al.  Lentiviral vectors derived from simian immunodeficiency virus. , 2002, Current topics in microbiology and immunology.

[49]  M. Sadelain,et al.  Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. , 2001, Blood.

[50]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.